Skip to main content

Advertisement

La nutraceutiques (alicaments) et compléments alimentaires dans le traitement de l’infertilité masculine

Nutraceuticals and food supplementation for the treatment of the subfertile male

Article metrics

  • 460 Accesses

Resume

Plusieurs essais contrôlés et correctement validés apportent des preuves que des compléments alimentaires contenant des substances particulières peuvent améliorer la qualité et la fonction spermatiques d’hommes hypofertiles. Parmi ces compléments figurent les antioxydants astaxanthine, tocophérols et ubiquinone Q10, des acides gras essentiels du groupe oméga 3, le zinc et l’acide folique. Il y a des études qui suggèrent que certains extraits de plantes et des lignans ont également des effets bénéfiques. L’administration d’un nutraceutique (Qualisperm ®, Nutriphyt, Oostkamp, Belgique) contenant ces substances augmente la probabilité d’une conception spontanée et d’une grossesse menée à terme. Bien que les mécanismes exacts de l’action de ces compléments alimentaires sur la spermatogenèse et la fonction spermatique n’aient pas encore été entièrement découverts, il semble concevable que ces compléments agissent directement sur les cellules de Sertoli et améliore la fonction épididymaire. En tant que compléments alimentaires exempts de toute toxicité, les nutraceutiques devraient également être pris en considération avant de procéder à une fertilisation in vitro et à une ICSI, afin de réduire les dégâts oxydatifs à l’ADN des spermatozoïdes.

Abstract

Several controlled and well-validated trials provide evidence that food supplementation with particular substances can improve semen quality and function of subfertile men. These include the antioxidants astaxanthin, tocopherols and ubiquinone Q10, essential fatty acids of the omega-3 group, zinc, and folic acid. There is suggestive evidence that certain plant extracts and lignans may equally exert beneficial effects. Supplementation with a nutraceutical (Qualisperm®, Nutriphyt, Oostkamp, Belgium) containing these substances increases the probability of spontaneous conception and successful pregnancy. Although the exact mechanisms of action of these supplements on spermatogenesis and sperm function remain to be unravelled, a direct effect on the cells of Sertoli and via epididymal function seems conceivable. Nutraceutical food supplementation should also be considered beforein vitro fertilization and ICSI, in order to reduce the oxidative damage to sperm DNA.

References

  1. 1.

    ADLERCREUTZ H., BANNWART C., WAHALA K. et al.: Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J. Steroid Biochem. Mol. Biol., 1993, 44: 147–153.

  2. 2.

    AYDIN S., INCI O., ALAGOL B.: The role of arginine, indomethacin and kallikrein in the treatment of oligoasthenospermia. Int. Urol. Nephrol., 1995, 27: 199–202.

  3. 3.

    BARTELLINI M., CANALE D., IZZO P.L., GIORGI P.M., MESCHINI P., MECHINI-FABRIS G.F.: L-carnitine and acetylcarnitine in human sperm with normal and reduced motility. Acta Eur. Fertil., 1987, 18: 29–31.

  4. 4.

    BAUMANN J., VON BRUCHHAUSEN F., WURM G.: Flavonoids and related compounds as inhibition of arachidonic acid peroxidation. Prostaglandins, 1980, 20: 627–639.

  5. 5.

    BERNARD D., CHRISTOPHE A., DELANGHE J., LANGLOIS M., DE BUYZERE M., COMHAIRE F.: The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox. Rep., 2003, 8: 41–46.

  6. 6.

    BONDE J.P., JOFFE M., APOSTOLI P. et al.: Sperm count and chromatin structure in men exposed to inorganic lead: lowest adverse effect levels. Occup. Environ. Med., 2002, 59: 234–242.

  7. 7.

    CHO K.J., YUN C.H., PACKER L., CHUNG A.S.: Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann. N. Y. Acad. Sci., 2001, 928: 141–156.

  8. 8.

    CHRISTOPHE A., ZALATA A., MAHMOUD A., COMHAIRE F. Fatty acid composition of sperm phospholipids and its nutritional implications. Middle East Fert. Soc. J., 1998, 3: 46–53.

  9. 9.

    CINTI D.L., COOK L., NAGI M.N., SUNEJA S.K.: The fatty acid chain elongation system of mammalian endoplasmic reticulum. Prog. Lipid Res., 1992, 31: 1–51.

  10. 10.

    COMHAIRE F.: Clinical andrology: from evidence-base to ethics. The ‘E’ quintet in clinical andrology. Hum. Reprod., 2000, 15: 2067–2071.

  11. 11.

    COMHAIRE F., VERMEULEN L.: Effect of high dose oral Kallikrein treatment in men with idiopathic subfertility: evaluation by means of in vitro penetration test of zona free hamster ova. Int. J. Androl., 1983, 6: 168–172.

  12. 12.

    COMHAIRE F.H., CHRISTOPHE A.B., ZALATA A.A., DHOOGE W.S., MAHMOUD A.M., DEPUYDT C.E.: The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot. Essent. Fatty Acids, 2000, 63: 159–165.

  13. 13.

    COMHAIRE F.H., GAREM Y.F.E., MAHMOUD A., EERTMANS F., SCHOONJANS F.: Combined conventional/antioxidant “Astaxanthin” treatment for male infertility: a double blind randomized trial. Asian J. Androl., 2004, sous presse.

  14. 14.

    COMHAIRE F.H., MAHMOUD A.M.: Editorial commentary. J. Androl., 2004, 25: 771–772.

  15. 15.

    COSTA M., CANALE D., FILICORI M., D’LDDIO S., LENZI A.: L-carnitine in idiopathic asthenozoospermia: a multicenter study. Italian Study Group on Carnitine and Male Infertility. Andrologia, 1994, 26: 155–159.

  16. 16.

    DAWSON E.B., HARRIS W.A., TETER M.C., POWELL L.C.: Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertil. Steril., 1992, 58: 1034–1039.

  17. 17.

    DE ALOYSIO D., MANTUANO R., MAULONI M., NICOLETTI G.: The clinical use of arginine aspartate in male infertility. Acta Eur. Fertil., 1982, 13: 133–167.

  18. 18.

    DEBAUN M.R., NIEMITZ E.L., FEINBERG A.P.: Association of in vitro fertilization with Beckwith-Wiedemann syndrome and epigenetic alterations of LIT1 and H19. Am. J. Hum. Genet., 2003, 72: 156–160.

  19. 19.

    DEPUYDT C.E., MAHMOUD A.M., DHOOGE W.S., SCHOONJANS F.A., COMHAIRE F.H.: Hormonal regulation of inhibin B secretion by immature rat sertoli cells in vitro: possible use as a bioassay for estrogen detection. J. Androl., 1999, 20: 54–62.

  20. 20.

    EDWARDS R.G., LUDWIG M.: Are major defects in children conceived in vitro due to innate problems in patients or to induced genetic damage? Reprod. Biomed. Online, 2003, 7: 131–138.

  21. 21.

    FRAGA C.G., MOTCHNIK P.A., SHIGENAGA M.K., HELBOCK H.J., JACOB R.A., AMES B.N.: Ascorbic acid protects against endogenous oxidative DNA damage in human sperm. Proc. Natl. Acad. Sci. U. S. A., 1991, 88: 11003–11006.

  22. 22.

    GOLAN R., WEISSENBERG R., LEWIN L.M.: Carnitine and acetylcarnitine in motile and immotile human spermatozoa. Int. J. Androl., 1984, 7: 484–494.

  23. 23.

    GONZALES G.F., CORDOVA A., GONZALES C., CHUNG A., VEGA K., VILLENA A.: Lepidium meyenii (Maca) improved semen parameters in adult men. Asian J. Androl., 2001, 3: 301–303.

  24. 24.

    GONZALES G.F., RUIZ A., GONZALES C., VILLEGAS L., CORDOVA A.: Effect of Lepidium meyenii (maca) roots on spermatogenesis of male rats. Asian J. Androl., 2001, 3: 231–233.

  25. 25.

    GOTO S., KOGURE K., ABE K. et al.: Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim. Biophys. Acta, 2001, 1512: 251–258.

  26. 26.

    GREEN N.S.: Risks of birth defects and other adverse outcomes associated with assisted reproductive technology. Pediatrics, 2004, 114: 256–259.

  27. 27.

    HANSEN M., KURINCZUK J.J., BOWER C., WEBB S.: The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. N. Engl. J. Med., 2002, 346: 725–730.

  28. 28.

    HUGHES C.M., LEWIS S.E., MCKELVEY-MARTIN V.J., THOMPSON W.: The effects of antioxidant supplementation during Percoll preparation on human sperm DNA integrity. Hum. Reprod., 1998, 13: 1240–1247.

  29. 29.

    HURTADO DE CATALFO G.E., DE GOMEZ DUMM I.N.: Polyunsaturated fatty acid biosynthesis from [1–14C]20:3 n-6 acid in rat cultured Sertoli cells. Linoleic acid effect. Int. J. Biochem. Cell Biol., 2002, 34: 525–532.

  30. 30.

    IRVINE D.S., TWIGG J.P., GORDON E.L., FULTON N., MILNE P.A., AITKEN R.J.: DNA integrity in human spermatozoa: relationships with semen quality. J. Androl., 2000, 21: 33–44.

  31. 31.

    IWAMOTO T., HOSODA K., HIRANO R. et al.: Inhibition of low-density lipoprotein oxidation by astaxanthin. J. Atheroscler. Thromb., 2000, 7: 216–222.

  32. 32.

    JEULIN C., LEWIN L.M. Role of free L-carnitine and acetyl-L-carnitine in post-gonadal maturation of mammalian spermatozoa. Hum. Reprod. Update, 1996, 2: 87–102.

  33. 33.

    KATZ P., NACHTIGALL R., SHOWSTACK J.: The economic impact of the assisted reproductive technologies. Nat. Cell Biol., 2002, 4 Suppl: s29-s32.

  34. 34.

    KENT-FIRST M.G., KOL S., MUALLEM A. et al.: The incidence and possible relevance of Y-linked microdeletions in babies born after intracytoplasmic sperm injection and their infertile fathers. Mol. Hum. Reprod., 1996, 2: 943–950.

  35. 35.

    KESSOPOULOU E., POWERS H.J., SHARMA K.K. et al.: A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertil. Steril., 1995, 64: 825–831.

  36. 36.

    KOHENGKUL S., TANPHAICHITR V., MUANGMUN V., TANPHAICHITR N.: Levels of L-carnitine and L-O-acetylcarnitine in normal and infertile human semen: a lower level of L-O-acetycarnitine in infertile semen. Fertil. Steril., 1977, 28: 1333–1336.

  37. 37.

    KOUDSTAAL J., BRUINSE H.W., HELMERHORST F.M., VERMEIDEN J.P., WILLEMSEN W.N., VISSER G.H. Obstetric outcome of twin pregnancies after in vitro fertilization: a matched control study in four Dutch University hospitals. Hum. Reprod., 2000, 15: 935–940.

  38. 38.

    LAMBERT R.D.: Safety issues in assisted reproduction technology: the children of assisted reproduction confront the responsible conduct of assisted reproductive technologies. Hum. Reprod., 2002, 17: 3011–3015.

  39. 39.

    LENZI A., CULASSO F., GANDINI L., LOMBARDO F., DONDERO F.: Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. Hum. Reprod., 1993, 8: 1657–1662.

  40. 40.

    LENZI A., LOMBARDO F., SGRO P. et al.: Use of carnitine therapy in selected cases of male factor infertility: a doubleblind crossover trial. Fertil. Steril., 2003, 79: 292–300.

  41. 41.

    LEWIN A., LAVON H.: The effect of coenzyme Q10 on sperm motility and function. Mol. Aspects Med., 1997, 18 Suppl: S213–9.

  42. 42.

    MA K., SHARKEY A., KIRSCH S. et al.: Towards the molecular localisation of the AZF locus: mapping of microdeletions in azoospermic men within 14 subintervals of interval 6 of the human Y chromosome. Hum. Mol. Genet., 1992, 1: 29–33.

  43. 43.

    MAHER E.R., AFNAN M., BARRATT C.L.: Epigenetic risks related to assisted reproductive technologies: epigenetics, imprinting, ART and icebergs? Hum. Reprod., 2003, 18: 2508–2511.

  44. 44.

    MAHMOUD A., KISS P., KAUFMAN J.M., COMHAIRE F., ASCLEPIOS: The influence of age and lead exposure on inhibin B serum levels in men. Int. J. Androl., 2000, 23 (suppl. 1): PO94.

  45. 45.

    MAHMOUD A.M., COMHAIRE F.H., DEPUYDT C.E.: The clinical and biological significance of serum inhibins in subfertile men. Reprod. Toxicol., 1998, 12: 591–599.

  46. 46.

    MAYERHOFER A., MEINEKE V., KÖHN F.M., FRUNGIERI M.: Cyclooxygenase (COX-2) in male infertility: a new link between prostaglandins and testicular fibrosis? Andrologia, 2002, 34: 272–273.

  47. 47.

    MEACHEM S.J., NIESCHLAG E., SIMONI M.: Inhibin B in male reproduction: pathophysiology and clinical relevance. Eur. J. Endocrinol., 2001, 145: 561–571.

  48. 48.

    MENCHINI-FABRIS G.F., CANALE D., IZZO P.L., OLIVIERI L., BARTELLONI M.: Free L-carnitine in human semen: its variability in different andrologic pathologies. Fertil. Steril., 1984, 42: 263–267.

  49. 49.

    MOLL A.C., IMHOF S.M., CRUYSBERG J.R., SCHOUTEN-VAN MEETEREN A.Y., BOERS M., VAN LEEUWEN F.E.: Incidence of retinoblastoma in children born after in vitro fertilisation. Lancet, 2003, 361: 309–310.

  50. 50.

    MONCADA M.L., VICARI E., CIMINO C., CALOGERO A.E., MONGIOI A., D’AGATA R.: Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Eur. Fertil., 1992, 23: 221–224.

  51. 51.

    PALERMO G., JORIS H., DEVROEY P., VAN STEIRTEGHEM A.C.: Pregnancies after intracytoplasmic injection of single spermatozoon into an oocyte. Lancet, 1992, 340: 17–18.

  52. 52.

    PINBORG A., LOFT A., SCHMIDT L., GREISEN G., RASMUSSEN S., ANDERSEN A.N.: Neurological sequelae in twins born after assisted conception: controlled national cohort study. Br. Med. J., 2004, 329: 311.

  53. 53.

    PRYOR J.P., BLANDY J.P., EVANS P., CHAPUT D.S.D., USHERWOOD M.: Controlled clinical trial of arginine for infertile men with oligozoospermia. Br. J. Urol., 1978, 50: 47–50.

  54. 54.

    ROHDEWALD P.: A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int. J. Clin. Pharmacol. Ther., 2002, 40: 158–168.

  55. 55.

    ROLF C., COOPER T.G., YEUNG C.H., NIESCHLAG E.: Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, doubleblind study. Hum. Reprod., 1999, 14: 1028–1033.

  56. 56.

    ROSEFF S.J., GULATI R.: Improvement of sperm quality by Pycnogenol. Eur. Bull. Drug Res., 1999, 7: 33–36.

  57. 57.

    RUIZ-PESINI E., ALVAREZ E., ENRIQUEZ J.A., LOPEZ-PEREZ M.J.: Association between seminal plasma carnitine and sperm mitochondrial enzymatic activites. Int. J. Androl., 2001, 24: 335–340.

  58. 58.

    SAETHER T., TRAN T.N., ROOTWELT H., CHRISTOPHERSEN B.O., HAUGEN T.B.: Expression and regulation of delta5-desaturase, delta6-desaturase, stearoyl-coenzyme A (CoA) desaturase 1, and stearoyl-CoA desaturase 2 in rat testis. Biol. Reprod., 2003, 69: 117–124.

  59. 59.

    SCHIEVE L.A., RASMUSSEN S.A., BUCK G.M., SCHENDEL D.E., REYNOLDS M.A., WRIGHT V.C.: Are children born after assisted reproductive technology at increased risk for adverse health outcomes? Obstet. Gynecol., 2004, 103: 1154–1163.

  60. 60.

    SCHILL W.B., KRIZIC A., RJOSK H.: Determination of various semen parameters and sex hormone levels in subfertile men during kallikrein therapy. Adv. Exp. Med. Biol., 1979, 120A: 537–546.

  61. 61.

    SCOTT R., MACPHERSON A., YATES R.W., HUSSAIN B., DIXON J.: The effect of oral selenium supplementation on human sperm motility. Br. J. Urol., 1998, 82: 76–80.

  62. 62.

    SHARPE R.M. The ‘oestrogen hypothesis’-where do we stand now? Int. J. Androl., 2003, 26: 2–15.

  63. 63.

    SKAKKEBAEK N.E.: Testicular dysgenesis syndrome: new epidemiological evidence. Int. J. Androl., 2004, 27: 189–191.

  64. 64.

    SOUFIR J.C., DUCOT B., MARSON J. et al.: Levels of seminal free L(−) carnitine in fertile and infertile men. Int. J. Androl., 1984, 7: 188–197.

  65. 65.

    STEPTOE P.C., EDWARDS R.G.: Birth after the reimplantation of a human embryo. Lancet, 1978, 2: 366.

  66. 66.

    STROMBERG B., DAHLQUIST G., ERICSON A., FINNSTROM O., KOSTER M., STJERNQVIST K.: Neurological sequelae in children born after in vitro fertilisation: a population-based study. Lancet, 2002, 359: 461–465.

  67. 67.

    SUTCLIFFE A.G., TAYLOR B., LI J., THORNTON S., GRUDZINSKAS J.G., LIEBERMAN B.A.: Children born after intracytoplasmic sperm injection: population control study. Br. Med. J., 1999, 318: 704–705.

  68. 68.

    TANPHAICHITR N.: In vitro stimulation of human sperm motility by acetylcarnitine. Int. J. Fertil., 1977, 22: 85–91.

  69. 69.

    TIEPOLO L., ZUFFARDI O.: Localization of factors controlling spermatogenesis in the nonfluorescent portion of the human Y chromosome long arm. Hum. Genet., 1976, 34: 119–124.

  70. 70.

    TRAN T.N., RETTERSTOL K., CHRISTOPHERSEN B.O.: Metabolism of long-chain polyunsaturated fatty acids in testicular cells. In: De Vriese S.R., Christophe A.B. eds. Male fertility and lipid metabolism. Illinois, AOCS Press, 2003: 11–22.

  71. 71.

    VAN DER VEN K., PESCHKA B., MONTAG M. et al.: Increased frequency of congenital chromosomal aberrations in female partners of couples undergoing intracytopiasmic sperm injection. Hum. Reprod., 1998, 13: 48–54.

  72. 72.

    VAN DISSEL-EMILIANI F.M., GROOTENHUIS A.J., DE JONG F.H., DE ROOLJ D.G.: Inhibin reduces spermatogonial numbers in testes of adult mice and Chinese hamsters. Endocrinology, 1989, 125: 1899–1903.

  73. 73.

    VANHOORNE M., COMHAIRE F., DE BACQUER D.: Epidemiological study of the effects of carbon disulfide on male sexuality and reproduction. Arch. Environ. Health, 1994, 49: 273–278.

  74. 74.

    VIRGILI F., KIM D., PACKER L.: Procyanidins extracted from pine bark protect alpha-tocopherol in ECV 304 endothelial cells challenged by activated RAW 264.7 macrophages: role of nitric oxide and peroxynitrite. FEBS Lett., 1998, 431: 315–318.

  75. 75.

    VITALI G., PARENTE R., MELOTTI C.: Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp. Clin. Res., 1995, 21: 157–159.

  76. 76.

    VOLIANI S., BERTOZZI M.A., ROSSI P., MENCHINI-FABRIS G.F.: The treatment of male infertility with L-carnitine/L-acetyl carnitine. XVII National Congress, Societa Italiana Andrologia SIA, Venezia 2001, 2001, 8: 122.

  77. 77.

    WANG C., MAKELA T., HASE T., ADLERCREUTZ H., KURZER M.S.: Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J. Steroid Biochem. Mol. Biol., 1994, 50: 205–212.

  78. 78.

    WENNERHOLM U., BERGH C., HAMBERGER L. et al.: Incidence of congenital malformations in children born after ICSI. Hum. Reprod., 2000, 15: 944–948.

  79. 79.

    WILDMAN R.E.C., MEDEIROS D.M.: Advanced human nutrition. London, CRC Press, 2000: 370–371.

  80. 80.

    WONG W.Y., MERKUS H.M., THOMAS C.M., MENKVELD R., ZIELHUIS G.A., STEEGERS-THEUNISSEN R.P.: Effects of folic acid and zinc sulfate on male factor subfertility: a doubleblind, randomized, placebo-controlled trial. Fertil. Steril., 2002, 77: 491–498.

  81. 81.

    ZALATA A.A., CHRISTOPHE A.B., DEPUYDT C.E., SCHOONJANS F., COMHAIRE F.H.: The fatty acid composition of phospholipids of spermatozoa from infertile patients. Mol. Hum. Reprod., 1998, 4: 111–118.

  82. 82.

    ZHENG B.L., HE K., KIM C.H. et al.: Effect of a lipidic extract from lepidium meyenii on sexual behavior in mice and rats. Urology, 2000, 55: 598–602.

Download references

Author information

Correspondence to Frank Comhaire.

Additional information

Communication au XXIo Congrès de la Société d’Andrologie de Langue Française, Clermont-Ferrand, 9–11 Décembre 2004.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Comhaire, F., Mahmoud, A. La nutraceutiques (alicaments) et compléments alimentaires dans le traitement de l’infertilité masculine. Androl. 15, 41–47 (2005) doi:10.1007/BF03035189

Download citation

Mots clés

  • nutraceutiques
  • alicaments
  • infertilité
  • antioxydants
  • ADN oxydé
  • acides gras

Key words

  • nutraceuticals
  • infertility
  • fatty acids
  • antioxidants
  • astaxanthin